Biohit Oyj (BIOBV) Stock Overview

Biohit Oyj, a biotechnology company, produces bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel test, a diagnostic test for dyspeptic patients; Biohit Active B12, a test for measuring the levels of active vitamin B12; BIOHIT Total 25OH Vitamin D, a test to recognize vitamin D2 and D3 for correct vitamin D deficiency from blood sample; Biohit Calprotectin that enables determination between inflammatory bowel diseases and irritable bowel syndrome non-invasively from a stool sample; Helicobacter Pylori Quick test and Biohit Helicobacter Pylori UFT300 Quick test, a test method to detect H. pylori infection from a biopsy sample; Biohit ColonView Quick test, a test for detection of fecal occult blood; BIOHIT Celiac Quick test for diagnosis of celiac disease from fingertip blood sample; Lactose Intolerance Quick test for detecting lactose intolerance in a biopsy specimen; and GA-map Dysbiosis test, a gut microbiota DNA analysis tool. It also provides monoclonal antibodies for use in the areas of cellular pathology, neurobiology, oncology, and human gastric biomarkers research. In addition, the company offers acetaldehyde binding products, such as Acetium capsules that are intended for persons with a low-acid or anacidic stomach; and Acetium lozenge, which helps in quitting smoking. The company was incorporated in 1988 and is headquartered in Helsinki, Finland.